← Back to the page you were readingYou opened this term from another page.
IP · Patent strategyTask: Check a product

Evergreening

Published by Patsnap Team Updated 3 sources
Definition

Evergreening is a label used by the generics industry for patent strategies facilitating switches to follow-up inventions or second-generation products, as recorded in the European Commission's 2009 Pharmaceutical Sector Inquiry1. The European Commission's 2009 inquiry notes that these terms are not defined in patent legislation1.

The European Commission's 2009 inquiry records generics' criticism of patent strategies supporting switches to follow-up inventions or second-generation products in paragraph 4801. The European Commission's 2009 inquiry also records originators' view that incremental innovations may meet unmet or differentiated consumer needs in paragraph 9931.

Used byThe European Commission's 2009 inquiry records the generics industry's use of the label1.
Comes upThe European Commission's 2009 inquiry discusses follow-up inventions and second-generation products1.
AppliesThe European Commission's 2009 inquiry uses the label as industry terminology1.
Not to confuse withThe European Commission's 2009 inquiry says the term is not defined in patent legislation1.
01

Two viewpoints in the same report

ViewpointWhat the report records
Generics industryThe European Commission's 2009 inquiry, paragraph 480, reports the evergreening criticism of strategies facilitating switches to follow-up inventions or second-generation products1
Originator companiesThe European Commission's 2009 inquiry, paragraph 993, reports their view that even small incremental innovations may address unmet or differentiated consumer needs1
02

The label in a US consultation

The USPTO's 2022 notice at 87 FR 67019 included remaining open to discussions of the FDA's concerns about practices referred to as evergreening, patent thickets, and product hopping2.

The USPTO's 2022 notice sought public input on collaboration initiatives between the USPTO and FDA2.

03

What the Indian Supreme Court said

In Novartis AG v. Union of India (2013), paragraph 191, the Supreme Court of India held that the beta crystalline form of Imatinib Mesylate at issue did not meet section 3(d)3.

In the same paragraph, the Court expressly said this did not mean section 3(d) bars patent protection for all incremental inventions of chemical and pharmaceutical substances3.

04

Questions people ask

Patsnap EurekaEureka IP

Check a product

FTO Search AI Agent

An AI agent that finds in-force patents that could read on your product, with a claim chart for each one.

Run FTO Search
Is evergreening itself a defined statutory patent category?

No, the European Commission's 2009 inquiry uses industry terminology subject to its express caveat that these concepts are not defined in patent legislation1.

Does every incremental pharmaceutical invention fail section 3(d)?

No, paragraph 191 of Novartis expressly says section 3(d) does not bar patent protection for all incremental inventions of chemical and pharmaceutical substances3.

What do originator companies say about follow-on products?

The European Commission's 2009 inquiry, paragraph 993, records their view that even small incremental innovations may produce products meeting unmet or differentiated consumer needs1.

05

How it connects

Builds onPatent
Next step

Go from the term to the task

Read how the method works, run it on your own product or idea, then try a free tool.

  • 01 / How-toHow to run a freedom-to-operate analysisScope, search, claim review and the report counsel will ask for.GuideRead
  • 02 / AI agentFTO Search AI AgentAn AI agent that finds in-force patents that could read on your product, with a claim chart for each one.Patsnap EurekaRun it
PublishedPatsnap Team
Updated 17 November 2026
Sources
  1. Pharmaceutical Sector Inquiry: Final Report. European Commission · report · 2009. Accessed 17 November 2026.
  2. Joint USPTO-FDA Collaboration Initiatives; Notice of Public Listening Session and Request for Comments. USPTO · Federal Register notice · 2022. Accessed 17 November 2026.
  3. Novartis AG v. Union of India & Others, Civil Appeal Nos. 2706-2716 of 2013. Supreme Court of India · judgment · 2013. Accessed 17 November 2026.
Disclaimer

General information only. This page explains a term for general information and reference only. It is not legal, accounting, tax or other professional advice and must not be relied upon as such. It does not create an attorney-client or other professional relationship.

Sources and accuracy. Statements on this page are intended to be either general background or linked to a source listed under Sources. The explanations summarize and simplify those sources and leave out detail. Where this page differs from a cited source or from the current official text of a law or standard, rely on that source or text. To the extent permitted by law, this page is provided as is, without any warranty that it is complete, accurate or current, and Patsnap accepts no liability for loss arising from reliance on it. See also Patsnap’s website Disclaimer.

Rules vary and change. The law, standards and practice described here differ between jurisdictions and change through legislation, court decisions and revisions to official guidance and standards. This page was last checked against its sources on 17 November 2026 and may not reflect later changes. Check the current rules and official guidance in each jurisdiction that applies to you.

No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.

Cases and records as examples. Court decisions, dockets, agency decisions and official reports are cited to show how a term is used, and are summarized rather than reproduced in full. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed, beyond what the cited record or decision itself states.

Third-party names, marks and links. Names of courts, government bodies, parties, people, companies, standards and products appear for identification only. Some of these names are trademarks of their owners; their appearance does not, by itself, imply affiliation with or endorsement by Patsnap. Links to third-party sources are provided for reference, and Patsnap is not responsible for their content or availability.

Patsnap Eureka. Patsnap publishes this glossary and also offers Patsnap Eureka, a commercial product mentioned on this page. Those mentions describe what its tools are designed to do, not what they will find in a particular case. Their outputs are research aids and should be reviewed by a qualified professional before being relied on.

Corrections and requests. If you believe a statement on this page is inaccurate or out of date, use “Share feedback” at the bottom of this page and tell us which statement and why. If you are named on this page, or your concern is about legal rights or personal information, email legal@patsnap.com. We review reports and may correct or update the page.

FTO Search AI AgentRun FTO Search in Patsnap EurekaStart →

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.